- Patents on our antibiotic-free selection technology
On May 10, 2016 the USPTO issued a first patent to Syngulon for the use of bacteriocin/immunity in any bacteria, yeast or algae for “Controlled growth of microorganisms“.
On January 29, 2019, USPTO issued a second patent to Syngulon covering the use of bacteriocin/immunity for the “Controlled growth of microorganisms“s.
On August 30, 2022, USPTO issued a third patent to Syngulon covering the use of bacteriocin/immunity for the “Controlled growth of microorganisms“.
On May 13, 2025, USPTO issued a fourth patent to Syngulon covering the use of bacteriocin/immunity for the “Controlled growth of microorganisms“.
On March 19, 2024, USPTO issued a first patent “Fermentation Process” to Syngulon and Université libre de Bruxelles (ULB) that specifically claims the use of “immunity only” and the control of the selection circuit in accordance with production fermentation processes.
These issued patents covering our antibiotic-free selection technology are available for licensing in all fields of use on a non-exclusive base.
- Patents on bacteriocins for other applications
US Patent 11,492,651 / US Patent 12,195,780
On November 8, 2022 the USPTO issued a first patent to Syngulon on “Methods and compositions for making bacteriocin and antimicrobial peptides“. The second patent was issued on January 14, 2025.
On December 24, 2024 the USPTO issued a first patent to Syngulon on “Engineering Antimicrobial Peptides”.
On February 25, 2025 the USPTO issued a patent to Syngulon and Université Catholique de Louvain (UCLouvain) on “Peptides for inducing bacteriocin synthesis and methods to identify and/or select and/or optimize the same“.
Patents filed with support from the Wallonia Region of Belgium.
Other patent applications covering Syngulon’s technologies have been filed with USPTO or EPO in 2017, 2018, 2020, 2021, 2022, 2023 and 2024.
You must be logged in to post a comment.